Bank of New York Mellon Corp Has $183.46 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Bank of New York Mellon Corp cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,040,620 shares of the medical research company's stock after selling 42,234 shares during the quarter. Bank of New York Mellon Corp owned 0.59% of IQVIA worth $183,461,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IQV. Continuum Advisory LLC boosted its holdings in IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the last quarter. ST Germain D J Co. Inc. boosted its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in IQVIA by 10.7% during the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock worth $182,000 after buying an additional 90 shares during the last quarter. Finally, Private Trust Co. NA lifted its holdings in IQVIA by 22.4% during the 1st quarter. Private Trust Co. NA now owns 536 shares of the medical research company's stock worth $94,000 after buying an additional 98 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Robert W. Baird reduced their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. Barclays reduced their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. reduced their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $222.45.

IQVIA Price Performance

Shares of IQV traded down $2.80 during trading hours on Friday, hitting $162.73. 1,156,699 shares of the company were exchanged, compared to its average volume of 1,659,159. The company has a market capitalization of $28.15 billion, a PE ratio of 22.17, a PEG ratio of 1.84 and a beta of 1.30. The firm has a fifty day simple moving average of $151.77 and a 200-day simple moving average of $172.43. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. IQVIA's revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.54 earnings per share. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.